Nutex Health NUTX
- Market cap
- $1.4B
- PE
- 8.3×
- 9y median 11.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.7×
- EV/EBIT
- 3.8×
- Revenue, 12 months
- $846.7M
- +7% on a year ago
- Net margin
- 21.2%
- Free cash flow yield
- 19.1%
Nutex Health trades at 8.3× trailing earnings, cheaper than 83% of the last ten years. Revenue was $846.7M over the last twelve months, up 7% on a year earlier with a 21% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $62.7M+121% | $69.7M+30% | $67.5M+20% | $76.1M+29% | $78.8M+26% | $257.6M+270% | $211.8M+214% | $244M+221% | $267.8M+240% | $151.7M−41% | $216.5M+2% | $210.8M−14% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | $7.1M | $13.2M | $10.2M+110% | $22.6M+134% | $21.9M+210% | $141.6M+972% | $118.3M+1065% | $124.9M+454% | $154.9M+607% | $46.1M−67% | $91.7M−23% | $141.3M+13% |
| R&D | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SG&A | $7.8M+16% | $8.5M+253% | $8.7M+21% | $10.7M+9% | $9.9M+27% | $12.7M+50% | $10M+16% | $12.5M+17% | $11.3M+15% | $17.8M+40% | $14.4M+43% | $16.7M+33% |
| −$821.2K−100% | −$26.1M+352% | $1.4M | $5.3M | $9.7M | $114.3M | $80.7M+5464% | $33.7M+536% | $130.4M+1249% | $30.9M−73% | $81.3M+1% | $121.7M+261% | |
| Interest expense | $4.1M+20% | $4.2M+48% | $4.4M+42% | $5.1M+4% | $5.4M+31% | $5.1M+19% | $6.1M+38% | $5.7M+12% | $5.5M+1% | $5M−2% | $4.7M−24% | $4.7M−18% |
| Pre-tax income | −$4.9M−99% | −$30.7M+247% | −$152K−98% | $3.9M | −$2.6M−47% | $108.7M | $71.2M | $23.7M+508% | $123.9M | $25.9M−76% | $76.6M+8% | $117.1M+393% |
| −$342.3K−96% | −$3M | $389.7K | $893.9K | $4.6M | $8.6M | $20.4M+5138% | $7.6M+749% | $27.1M+492% | $9.3M+8% | $13.8M−32% | $20.8M+174% | |
| Net income | −$5.5M−99% | −$31.6M+114% | −$364.1K−93% | −$364K−90% | −$8.8M+59% | $61.6M | $21.2M | −$17.7M+4761% | $55.4M | $11.8M−81% | $46.8M+121% | $65.8M |
| −$1.25−87% | −$7.06+2253% | −$0.08−33% | −$0.07−91% | −$1.72+38% | $10.55 | $3.33 | −$2.95+4114% | $7.76 | $1.74−84% | $6.52+96% | $9.38 | |
| 4.4M−90% | 4.5M−90% | 4.8M−89% | 5M+14% | 5.1M+15% | 5.8M+30% | 6.5M+33% | 6M+21% | 7.2M+41% | 6.8M+17% | 7.2M+11% | 7M+17% |
EPS, diluted: 15 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 19 periods, Q1 FY11 to Q2 FY24: not printed by the filing, worked out from its own lines. 9 periods, Q4 FY11 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY13 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Financial - Credit Services nearest Nutex Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NUTXNutex Health | $1.4B | 8.3× | 11.0× | 1.7× | +7% | 21.2% | |
| LQDTLiquidity Services | $1.4B | 44.0× | 30.6× | 2.9× | +5% | 6.8% | |
| ATLCAtlanticus | $1.3B | 11.3× | 7.8× | 0.5× | +84% | 5.8% | |
| PGYPagaya Technologies | $1.6B | 13.9× | 14.2× | 1.1× | +20% | 9.1% | |
| HAPNHappen | $1.6B | 8.5× | 20.6× | 1.6× | +18% | 18.7% | |
| WDWalker & Dunlop | $1.2B | 30.5× | 12.7× | 0.9× | +8% | 3.0% | |
| JCAPJefferson Capital | $1.2B | 8.3× | 8.4× | 1.8× | +23% | 23.5% | |
| PWPPerella Weinberg Partners | $1.2B | 59.0× | 41.7× | 1.7× | −21% | 3.2% | |
| WUWestern Union CO | $2B | 5.2× | 7.9× | 0.5× | −2% | 9.8% | |
| ECPGEncore Capital | $2.1B | 7.4× | 7.2× | 1.1× | +30% | 15.9% | |
| AGMFederal Agricultural Mortgage | $2.2B | 10.9× | 10.3× | 4.9× | +15% | 51.4% | |
| Peer median | $1.5B | 11.1× | 11.5× | 1.3× | +17% | 9.4% |
More on Nutex Health
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 46Credit services stocks with the fastest earnings growth
- #7of 133Financial stocks with the lowest EV/EBIT
- #6of 70Credit services stocks with the lowest EV/EBIT
- #10of 111Financial stocks with the highest free cash flow yield
- #10of 59Credit services stocks with the highest free cash flow yield
Its groups
About
- Industry
- Financial - Credit Services
- Sector
- Financial Services
Valuation data, not investment advice. Prices as of .